Sponsor or institution
Clinical trials and research at Henan Cancer Hospital
As of November 12, 2026, Find a Trial lists 55 clinical trials run by Henan Cancer Hospital that are recruiting, in China. By phase: Phase 2 (28), Phase 3 (6), Phase 1/2 (5), Phase 1 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 55Clinical trials
- 1Country
Newest trials
All recruiting trials (55)
-
Testing WJ01024 Alone and with Ruxolitinib for Myelofibrosis with Splenomegaly
This early-phase study tests whether WJ01024, by itself or with ruxolitinib, is safe and tolerable and whether it shows signs of activity in adults with myelofibrosis and enlarged spleen.
-
Surgery or chemoradiotherapy after neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma
In people with locally advanced ESCC who respond to neoadjuvant immunochemotherapy, this study tests whether organ preservation with treatment other than surgery can be as effective as radical esophagectomy.
-
Adebrelimab consolidation after chemoradiotherapy for limited-stage small-cell lung cancer
This study tests whether adding adebrelimab after chemoradiotherapy helps patients with untreated limited-stage small-cell lung cancer see better outcomes.
-
Intrathecal methotrexate-loaded tumor-derived vesicles for leptomeningeal lung cancer
This treatment will try giving methotrexate-loaded tumor-derived vesicles into the spinal fluid to see if it is safe and helps adults with leptomeningeal metastasis from lung cancer who have not responded to standard treatments.
-
Toripalimab plus doctor‑chosen chemotherapy for advanced HER2‑negative breast cancer
This trial will test whether adding the PD‑1 drug toripalimab to a chemotherapy regimen chosen by your doctor helps people with recurrent or metastatic HER2‑negative breast cancer who have already had prior systemic therapy.
-
Fruquintinib with trastuzumab and XELOX for first-line treatment of HER2‑positive advanced stomach or GEJ cancer
This trial will try fruquintinib together with trastuzumab and XELOX to see if it helps people with HER2‑positive advanced stomach or gastroesophageal junction cancer as their first treatment.
-
BioTTT001 injection for meningeal metastasis from recurrent non‑small cell lung cancer
This trial will test whether injecting BioTTT001, an oncolytic adenovirus carrying nsIL12, into the cerebrospinal fluid helps people with recurrent or progressive non‑small cell lung cancer that has spread to the meninges.
-
Using T-cell receptor patterns to predict response to first-line tislelizumab plus chemotherapy in extensive-stage small-cell lung cancer
This will test whether patterns in patients' T-cell receptors can predict how well first-line tislelizumab plus chemotherapy works for people with extensive-stage small-cell lung cancer.
-
Zanubrutinib plus rituximab as first-line treatment for marginal zone lymphoma
This tests whether combining zanubrutinib and rituximab is effective and safe as first-line treatment for people with CD20-positive marginal zone lymphoma who have not received prior systemic therapy.
-
Efbemalenograstim alfa to prevent febrile neutropenia in people with solid tumors at high or intermediate risk
This will test whether giving efbemalenograstim alfa injections can prevent fever with low white blood cells in adults with solid tumors who are receiving high-risk or intermediate-risk chemotherapy with additional risk factors.
-
Shr2554 plus endocrine therapy in advanced breast cancer
This study tests whether an all-oral SHR2554 combined with HRS-8080 can be safe and show preliminary activity in adults with advanced breast cancer.
-
Trastuzumab rezetecan with or without radiotherapy for HER2‑positive advanced breast cancer that has spread to the brain.
This trial will test whether adding radiotherapy to trastuzumab rezetecan helps adults with HER2‑positive advanced breast cancer and untreated brain metastases control their brain tumors better than the drug alone.
-
Comparing nab‑paclitaxel versus docetaxel plus carboplatin with trastuzumab and pertuzumab for HER2‑positive early breast cancer neoadjuvant treatment
This trial will test whether nab‑paclitaxel combined with trastuzumab and pertuzumab works as well as the standard docetaxel‑and‑carboplatin regimen with the same antibodies for people with HER2‑positive early breast cancer before surgery.
-
One-stage prepectoral implant versus two-stage expander-to-implant breast reconstruction after mastectomy and radiotherapy
This compares immediate one-stage prepectoral implant reconstruction with two-stage expander-to-implant reconstruction in women who will have radiotherapy after mastectomy to see if one approach gives better quality of life and fewer complications.
-
Laparoscopic nipple- and areola-sparing mastectomy with immediate implant, patch, and fat grafting reconstruction
This will test whether laparoscopic nipple- and areola-sparing mastectomy with an immediate pectoral-muscle implant plus patch and same-time autologous fat grafting is safe and effective for women with early unilateral breast cancer (cT1-2N0M0).
-
Neoadjuvant QL1706 plus chemotherapy for early HR-positive/HER2-negative breast cancer
This trial tests whether adding QL1706 to pre-surgery chemotherapy improves the chance of a complete tumor response in people with early HR+/HER2- breast cancer.
-
Personalized treatment for lung cancer patients with pleural effusion using organoids
This study is testing whether using lab-grown versions of lung cancer tumors can help doctors choose the best treatment for patients with lung cancer who have fluid buildup in their lungs.
-
Combining Furmonertinib and Anlotinib for Advanced Lung Cancer with Brain Metastasis
This study is testing if combining two drugs, Furmonertinib and Anlotinib, can help people with advanced lung cancer that has spread to the brain feel better and live longer.
-
SHR-A1811 and pertuzumab before surgery for HER2-positive breast cancer
This study tests whether adding SHR-A1811 to pertuzumab, with or without albumin-paclitaxel, helps people with early HER2-positive breast cancer reach a pathologic complete response before surgery.
-
Serplulimab plus nab-paclitaxel and epirubicin for early HR+/HER2- breast cancer
This Phase 2 study will test whether adding serplulimab to nab-paclitaxel and epirubicin before surgery helps shrink early-stage HR+/HER2- breast cancers in adults.
-
Combination therapy for early triple-negative breast cancer
This study is testing a new combination of medications to see if it helps people with early-stage triple-negative breast cancer respond better to treatment before surgery.
-
Combining Serplulimab with Chemotherapy for Early-stage HR+/HER2- Breast Cancer
This study is testing if adding a new drug called serplulimab to standard chemotherapy helps people with early-stage HR+/HER2- breast cancer have better outcomes before surgery.
-
Combining Fruquintinib with chemotherapy for treating gastric cancer after surgery
This study is testing if adding Fruquintinib to standard chemotherapy can help people with HER2-negative gastric cancer who had surgery and are at high risk of their cancer coming back.
-
Combining Adebrelimab with Apatinib and Gemcitabine/Cisplatin for treating advanced Biliary Tract Carcinoma
This study is testing a new combination of treatments for patients with advanced biliary tract cancer to see if it helps them more than standard chemotherapy alone.
-
Evaluating the effectiveness of PD-1 antibody therapy in cancer treatment
This study is testing how well PD-1 antibody therapy works and how safe it is for adults with cancer by looking at real-world treatment results.
-
ARX788 in HER2-positive metastatic breast cancer
This study tests ARX788 every 6 weeks in adults with HER2-positive metastatic breast cancer to see if it helps control tumors.
-
Evaluating lymph node dissection for breast cancer treatment
This study is testing if a specific type of surgery for breast cancer can help patients live longer and have fewer complications compared to regular radiation treatment.
-
Combining utidelone and capecitabine for treating brain metastases in triple-negative breast cancer
This study is testing a new combination of two medications, utidelone and capecitabine, to see if they can help people with brain metastases from triple-negative breast cancer.
-
RE002 T‑cell injection for KRAS G12D mutated solid tumors
This trial tests whether a personalized RE002 T‑cell infusion is safe and can shrink tumors in adults with advanced solid tumors that have a KRAS G12D mutation and are HLA‑A*11:01 positive.
-
Evaluating Axillary Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Breast Cancer Patients
This study is trying to see if a specific type of lymph node surgery is safe and effective for breast cancer patients who have had chemotherapy and show no signs of cancer in their lymph nodes.
-
Using Palbociclib for Advanced Liver Cancer Treatment
This study is testing if the drug palbociclib can help people with advanced liver cancer who haven't had success with other treatments.
-
Combining linperlisib and chidamide for treating peripheral T-cell lymphoma
This study is testing a new combination of two drugs, linperlisib and chidamide, to see if it can help people with peripheral T-cell lymphoma more than the usual chemotherapy treatment.
-
Combination treatment for advanced gastric cancer
This study is testing a new combination of treatments for people with advanced stomach cancer to see if it can help improve their health and fight the disease better.
-
Combining TAS-102 with Bevacizumab for Advanced Colorectal Cancer Treatment
This study is testing if combining two drugs, TAS-102 and bevacizumab, can help people with advanced colorectal cancer stay healthy longer compared to the usual chemotherapy treatment.
-
Combining Darsilide with Trastuzumab and Patuzumab for Breast Cancer Treatment
This study is testing if a new treatment combining Darsilide with two other drugs can help women with early or locally advanced HER2-positive breast cancer before they have surgery.
-
Maintenance treatment for AML patients using ITIVA
This study is testing a new combination of treatments for people with Acute Myeloid Leukemia to see if it helps those who still have signs of the disease after chemotherapy and those who don’t.
-
Comparing two treatment approaches for advanced breast cancer
This study is testing which treatment works better for people with advanced breast cancer that has low hormone receptor expression and is HER2-negative: a combination of chemotherapy and maintenance therapy or a CDK4/6 inhibitor with hormone therapy.
-
Comparing two treatments for HER2-positive breast cancer before surgery
This study is testing a new combination of drugs to see if it works better than standard treatment for people with HER2-positive breast cancer before surgery.
-
Neoadjuvant treatment for HR-positive, low HER2 breast cancer
This study is testing a new treatment called SHR-A1811 to see if it can help people with early-stage HR-positive, low HER2 breast cancer before they have surgery.
-
Using SHR-A1811 for HER2-positive advanced breast cancer with brain metastases
This study is testing a new treatment called SHR-A1811 for women with advanced HER2-positive breast cancer that has spread to the brain to see if it helps them better than current options.
-
Using Lenvatinib for treating advanced bone and soft tissue sarcomas
This study is testing if a new medication called lenvatinib can help people with advanced bone and soft tissue sarcomas who haven't had success with other treatments.
-
Long-term follow-up of anxiety and depression in cancer patients
This study is trying to see how anxiety and depression affect cancer patients over time and how it relates to their treatment and recovery.
-
Using Sintilimab to treat advanced esophageal cancer after surgery
This study is testing if the immunotherapy drug Sintilimab can help people with advanced esophageal cancer who are at high risk of their cancer coming back after surgery.
-
Combining Camrelizumab with TCb for treating triple-negative breast cancer
This study is testing if combining a new drug called camrelizumab with a chemotherapy treatment can help people with triple-negative breast cancer do better after surgery.
-
Collecting data on bone and soft tissue tumors
This study is collecting information from patients with bone and soft tissue tumors at Henan Cancer Hospital over the next ten years to see how their treatment and outcomes change over time.
-
Utidelone plus bevacizumab for people with HER2-negative advanced breast cancer after at least two prior treatments
This trial will test whether combining utidelone with bevacizumab helps people who have HER2-negative advanced breast cancer and have already received two or more prior lines of therapy.
-
Using AK104 with chemotherapy for lung cancer treatment
This study is testing if adding a new drug called AK104 to standard chemotherapy can help people with early-stage lung cancer do better and feel safer during treatment.
-
Combining anlotinib and vinorelbine for HER2-negative advanced breast cancer
This study is testing if combining two drugs, anlotinib and vinorelbine, can help women with advanced HER2-negative breast cancer who haven't had success with other treatments.
-
Combining orelabrutinib and pemetrexed for treating relapsed central nervous system lymphoma
This study is testing if combining orelabrutinib with pemetrexed can help people with relapsed central nervous system lymphoma feel better and improve their treatment outcomes.
-
Combining capecitabine with endocrine therapy for HR+/HER2- breast cancer
This study is testing if adding capecitabine to standard hormone therapy can help women with hormone receptor-positive and HER2-negative breast cancer live longer without their cancer coming back.
-
Combining toripalimab with chemotherapy for advanced gastric cancer
This study is testing if combining a new drug called toripalimab with chemotherapy can help people with advanced stomach cancer do better before surgery.
-
Combination treatment for primary central nervous system lymphoma
This study is testing a new combination of medications to see if it can help people with primary central nervous system lymphoma feel better and improve their treatment outcomes.
-
Comparing immunochemotherapy and chemotherapy for esophageal cancer before surgery
This study is testing if a new combination of immunotherapy and chemotherapy can help people with esophageal cancer live longer and have better outcomes before surgery compared to standard chemotherapy.
-
Examining gene abnormalities and their impact on lymphoma prognosis
This study is trying to see how certain gene changes in lymphoma patients affect their treatment outcomes and overall health.
-
Comparing chemotherapy and chemoradiotherapy before surgery for esophageal cancer
This study is testing whether giving patients with esophageal cancer chemotherapy or a combination of chemotherapy and radiation before surgery helps them live longer.
Quick answers
How many clinical trials run by Henan Cancer Hospital are recruiting right now?
55, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 28, Phase 3: 6, Phase 1/2: 5, Phase 1: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.